Section snippets

Authors' contributions:

P.R., K.N.: Writing - Original Draft, Data curation, Formal Analysis; D.D.P, D.P.: Data curation, Formal Analysis, Writing - Review & Editing; D.A.S.: Conceptualization, Methodology, Formal Analysis, Writing – Review and Editing, Supervision.

Financial support:

NoneThe recently published multicenter study of Porto-Sinusoidal Vascular Disorder (PSVD) patients by Magaz and Giudicelli-Lett et al thoroughly details the clinical findings and disease progression of PSVD.¹ Given the rarity of PSVD yet improved prognosis with early recognition, the authors stress the importance of clinical awareness of associated conditions to expedite diagnosis. To this point, is it important to note that PSVD has also been observed in the setting of telomere biology

Declaration of Competing Interest:

DAS is funded by National Institute of Health U01AA026886–03. DAS has consulted for Mallinckrodt, Evive, Resolution Therapeutics, BioVie, AstraZeneca, Iota and PharmaIN.

中文翻译：

---

门窦血管疾病与端粒生物学疾病的关联认识不足

 部分片段

 作者贡献：

P.R.， K.N.： 写作 - 原稿、数据管理、形式分析;D.D.P.，D.P.：数据管理，形式分析，写作 - 审查和编辑;D.A.S.：概念化、方法论、形式分析、写作 - 审查和编辑、监督。

 资金支持：

无Magaz 和 Giudicelli-Lett 等人最近发表的波多窦血管疾病 （PSVD） 患者的多中心研究详细介绍了 PSVD 的临床发现和疾病进展。¹ 鉴于 PSVD 的罕见性，但早期识别可改善预后，作者强调了临床认识相关疾病对加快诊断的重要性。在这一点上，重要的是要注意 PSVD 也在端粒生物学的背景下观察到

利益争夺声明：

DAS 由美国国立卫生研究院 U01AA026886-03 资助。DAS 曾为 Mallinckrodt、Evive、Resolution Therapeutics、BioVie、AstraZeneca、Iota 和 PharmaIN 提供咨询服务。